Kawasaki Disease After Vaccination
Authors:
- Wei HuaWHWei Hua
- Hector S. IzurietaHIHector S. Izurieta
- Barbara SladeBSBarbara Slade
- Ermias D. BelayEBErmias D. Belay
- Penina HaberPHPenina Haber
- Rosemary TiernanRTRosemary Tiernan
- Emily Jane WooEWEmily Jane Woo
- John IskanderJIJohn Iskander
- M Miles BraunMBM Miles Braun
- Robert MD BallRBRobert MD Ball
- 1 November 2009
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 28 (11) , 943-947
Abstract
Background: Kawasaki disease (KD) is a multisystemic vasculitis primarily affecting children <5 years. A review of RotaTeq (rotavirus vaccine live) clinical trial data revealed higher, though not statistically significantly, KD rates among RotaTeq vaccines than placebo recipients. In June 2007, the RotaTeq label was revised accordingly. Objectives: To describe and assess KD reported to Vaccine Adverse Event Reporting System (VAERS) for all US licensed vaccines. Methods: We reviewed all KD reports received by VAERS from 1990 through mid-October 2007. Cases were characterized by age, gender, onset interval, and vaccine type. Proportional reporting ratio (PRR) was used to evaluate KD reporting for each vaccine compared with all others. Reporting rates were calculated using number of doses distributed as denominator. Results: Through October14, 2007, 107 KD reports were received by VAERS: 26 were categorized as classic cases, 19 atypical, 52 possible, and 10 were noncases. Of the 97 cases, 91% were children <5 years. There was no clustering of onset intervals after day 1 postvaccination. Before the RotaTeq label revision, the KD PRR was elevated only for Pediarix (DTaP, hepB, and IPV combined) but the KD reporting rate for Pediarix (0.59/100,000 person-years) was much lower than the background incidence rate (9–19/100,000 person-years) for children <5 years in the United States. After the revision, reporting of KD for RotaTeq was stimulated but the reporting rate for RotaTeq (1.47/100,000 person-years) was still much lower than the background rate. Conclusions: Our review does not suggest an elevated KD risk for RotaTeq or other vaccines. Continued postmarketing monitoring for KD is ongoing.Keywords
This publication has 22 references indexed in Scilit:
- New developments in the search for the etiologic agent of Kawasaki diseaseCurrent Opinion in Pediatrics, 2007
- Incidence of Kawasaki disease in Japan: the nationwide surveys of 1999–2002Pediatrics International, 2006
- Kawasaki disease: What is the epidemiology telling us about the etiology?International Journal of Infectious Diseases, 2005
- Advances in Kawasaki diseaseEuropean Journal of Pediatrics, 2004
- Kawasaki Syndrome Hospitalizations in the United States, 1997 and 2000Pediatrics, 2003
- Kawasaki disease: etiology, pathogenesis, and treatment.Cleveland Clinic Journal of Medicine, 2002
- The incidence of Kawasaki syndrome in West Coast health maintenance organizationsThe Pediatric Infectious Disease Journal, 2000
- Kawasaki Disease: A Brief HistoryPediatrics, 2000
- KAWASAKI SYNDROMEPediatric Clinics of North America, 1999
- Kawasaki SyndromeClinical Microbiology Reviews, 1998